E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Kowa’s selective PPARα modulator “K-808” (pemafibrate) has been granted “breakthrough therapy” designation by the US FDA for the treatment of primary biliary cholangitis.
imphoenix82
Unlike many existing treatments for fatty liver disease that mainly focus on weight loss, this new experimental drug targets the disease process itself.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
